Your browser doesn't support javascript.
loading
Trimerization and Genotype-Phenotype Correlation of COL4A5 Mutants in Alport Syndrome.
Kamura, Misato; Yamamura, Tomohiko; Omachi, Kohei; Suico, Mary Ann; Nozu, Kandai; Kaseda, Shota; Kuwazuru, Jun; Shuto, Tsuyoshi; Iijima, Kazumoto; Kai, Hirofumi.
Afiliação
  • Kamura M; Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
  • Yamamura T; Program for Leading Graduate Schools "HIGO (Health life science: Interdisciplinary and Global Oriented) Program", Kumamoto University, Kumamoto, Japan.
  • Omachi K; Department of Pediatrics, Graduate School of Medicine, Kobe University, Kobe, Japan.
  • Suico MA; Department of Medicine, Division of Nephrology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Nozu K; Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
  • Kaseda S; Department of Pediatrics, Graduate School of Medicine, Kobe University, Kobe, Japan.
  • Kuwazuru J; Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
  • Shuto T; Program for Leading Graduate Schools "HIGO (Health life science: Interdisciplinary and Global Oriented) Program", Kumamoto University, Kumamoto, Japan.
  • Iijima K; Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
  • Kai H; Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
Kidney Int Rep ; 5(5): 718-726, 2020 May.
Article em En | MEDLINE | ID: mdl-32405592
ABSTRACT

INTRODUCTION:

Alport syndrome is a hereditary glomerulonephritis that results from the disruption of collagen α345(IV) heterotrimerization caused by mutation in COL4A3, COL4A4 or COL4A5 genes. Many clinical studies have elucidated the correlation between genotype and phenotype, but there is still much ambiguity and insufficiency. Here, we focused on the α345(IV) heterotrimerization of α5(IV) missense mutant as a novel factor to further understand the pathophysiology of Alport syndrome.

METHODS:

We selected 9 α5(IV) missense mutants with typical glycine substitutions that clinically differed in disease progression. To quantify the trimerization of each mutant, split nanoluciferase-fused α3/α5 mutants and α4 were transfected into the cells, and intracellular and secreted heterotrimer were detected by luminescence using an assay that we developed previously.

RESULTS:

Trimer formation and secretion patterns tended to be similar to the wild type in most of the mutations that did not show proteinuria at a young age. On the other hand, trimer secretion was significantly reduced in all the mutations that showed proteinuria and early onset of renal failure. One of these mutants has low ability of intracellular trimer formation, and the others had the defect of low-level secretion. In addition, the mutant that is assumed to be nonpathogenic has similar trimer formation and secretion pattern as wild-type α5(IV).

CONCLUSION:

The result of cell-based α345(IV) heterotrimer formation assay was largely correlated with clinical genotype-phenotype. These trimerization assessments provide additional phenotypic considerations and may help to distinguish between pathogenic and nonpathogenic mutations.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article